Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620225 · ClinicalTrials.gov registry record · NA
Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management
A NA study, sponsored by NeuraLace Medical.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT05620225: Completed NA study, sponsored by NeuraLace Medical.
NCT05620225 is a NA study that has completed, run by NeuraLace Medical. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05620225, a NA study, has completed, sponsored by NeuraLace Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
Primary Outcome
The primary efficacy endpoint is a between groups comparison of pain change from baseline to 30 days.
Interventions
- DEVICE Axon Therapy and CMM
- DEVICE Sham and CMM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2023-11-22 |
| Phase | NA |
What the finished NCT05620225 record still lists
NCT05620225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Axon Therapy and CMM is the first listed.
NCT05620225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05620225 about?
NCT05620225 is a clinical study titled "Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management". Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
What is the current status of trial NCT05620225?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2022-12-15. Estimated completion is 2023-11-22.
What interventions are being tested in trial NCT05620225?
The interventions under investigation include: Axon Therapy and CMM (DEVICE), Sham and CMM (DEVICE).
Who is sponsoring clinical trial NCT05620225?
This trial is sponsored by NeuraLace Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05620225's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI